**Editor**

Tore K Kvien

**Associate Editors**

Francis Berenbaum  
Hans Bijlsma  
David Pisetsky  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 9.270

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2014 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.  
Register using this QR code.

**Editorial**

- 1 IgG4 levels and plasmablasts as a marker for IgG4-related disease (IgG4-RD)  
*R I Fox, C M Fox*

**Viewpoint**

- 4 Reflecting on the global burden of musculoskeletal conditions: lessons learnt from the Global Burden of Disease 2010 Study and the next steps forward  
*D G Hoy, E Smith, M Cross, L Sanchez-Riera, F M Blyth, R Buchbinder, A D Woolf, T Driscoll, P Brooks, L M March*

**Recommendation**

- 8 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations  
*D van der Heijde, D Aletaha, L Carmona, C J Edwards, T K Kvien, M Kouloumas, P Machado, S Oliver, M de Wit, M Dougados*

**Clinical and epidemiological research**

- 14 The diagnostic utility of serum IgG4 concentrations in IgG4-related disease  
*M N Carruthers, A Khosroshahi, T Augustin, V Deshpande, J H Stone*
- 19 Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period  
*P Emery, G R Burmester, V P Bykerk, B G Combe, D E Furst, E Barré, C S Karyekar, D A Wong, T W J Huizinga*
- 27 Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial  
*P Verschuere, D De Cock, L Corluy, R Joos, C Langenaken, V Taelman, F Raeman, I Ravelinging, K Vandevyvere, J Lenaerts, E Geens, P Geusens, J Vanhoof, A Durnez, J Remans, B V Cruyssen, E Van Essche, A Sileghem, G De Brabanter, J Joly, S Meyfroidt, K Van der Elst, R Westhovens*
- 35 Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study  
*T W J Huizinga, P G Conaghan, E Martin-Mola, G Schett, H Amital, R M Xavier, O Troum, M Aassi, C Bernasconi, M Dougados*
- 44 Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study  
*A Kavanaugh, D Gladman, D van der Heijde, O Purcaru, P Mease*
- 52 Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study  
*S Ramiro, C Stoltwijk, A van Tubergen, D van der Heijde, M Dougados, F van den Bosch, R Landewé*
- 60 Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Trøndelag Health Study (HUNT)  
*M Hoff, A M Gulati, P R Romundstad, A Kavanaugh, G Haugeberg*
- 65 Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis  
*C Stoltwijk, A van Tubergen, J D Castillo-Ortiz, A Boonen*
- 74 Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham Heart Study  
*I K Haugen, V S Ramachandran, D Misra, T Neogi, J Niu, T Yang, Y Zhang, D T Felson*
- 82 Cross-sectional and longitudinal associations between circulating leptin and knee cartilage thickness in older adults  
*O P Stannus, Y Cao, B Antony, L Blizzard, F Cicuttini, G Jones, C Ding*
- 89 Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use  
*S M Proudman, M J James, L D Spargo, R G Metcalf, T R Sullivan, M Rischmueller, K Flabouris, M D Wechalekar, A T Lee, L G Cleland*
- 96 Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials  
*V P Bykerk, J Cush, K Winthrop, L Calabrese, O Lortholary, M de Longueville, R van Vollenhoven, X Mariette*
- 104 Responsiveness and minimally important difference for the Patient-Reported Outcomes Measurement Information System (PROMIS) 20-item physical functioning short form in a prospective observational study of rheumatoid arthritis  
*R D Hays, K L Spritzer, J F Fries, E Krishnan*
- 108 Self-management approaches for osteoarthritis in the hand: a 2x2 factorial randomised trial  
*K Dziedzic, E Nicholls, S Hill, A Hammond, J Handy, E Thomas, E Hay*

**MORE CONTENTS ►**

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme.  
See <http://ard.bmj.com/site/about/guidelines.xhtml#open>

C O P E COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics


<http://publicationethics.org/>



- 119** Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis  
*A M van Sijl, I C van Eijl, M J L Peters, E H Serné, I E van der Horst-Bruinsma, Y M Smulders, M T Nurmohamed*
- 124** Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre  
*G Lepri, S Guiducci, S Bellando-Randone, I Giani, C Bruni, J Blagojevic, G Carnesecchi, A Radicati, F Pucciani, M-C Marco*
- 129** The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK  
*J C Robson, A Kiran, J Maskell, A Hutchings, N Arden, B Dasgupta, W Hamilton, A Emin, D Culliford, R A Luqmani*
- 136** Erosive osteoarthritis: a more severe form of radiographic hand osteoarthritis rather than a distinct entity?  
*M Marshall, E Nicholls, W-Y Kwok, G Peat, M Kloppenburg, D van der Windt, H Myers, K Dziedzic*
- 142** Revisiting comorbidities in gout: a cluster analysis  
*P Richette, P Clerson, L Périssin, R-M Flipo, T Bardin*
- 148** Health status has improved more in women than in men with rheumatoid arthritis from 1994 to 2009: results from the Oslo rheumatoid arthritis register  
*C Austad, T K Kvien, I C Olsen, T Uhlig*
- 156** The population prevalence of symptomatic radiographic foot osteoarthritis in community-dwelling older adults: cross-sectional findings from the Clinical Assessment Study of the Foot  
*E Roddy, M J Thomas, M Marshall, T Rathod, H Myers, H B Menz, E Thomas, G Peat*
- 164** Exercise therapy may postpone total hip replacement surgery in patients with hip osteoarthritis: a long-term follow-up of a randomised trial  
*I Svege, L Nordsletten, L Fernandes, M A Risberg*
- 170** A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk  
*A Yarwood, B Han, S Raychaudhuri, J Bowes, M Lunt, D A Pappas, J Kremer, J D Greenberg, R Plenge, Rheumatoid Arthritis Consortium International (RACI), J Worthington, A Barton, S Eyre*
- 177** Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials  
*J Robson, H Doll, R Suppiah, O Flossmann, L Harper, P Höglund, D Jayne, A Mahr, K Westman, R Luqmani*
- 185** High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis  
*A L Tan, E Fukeba, N A Halliday, S F Tanner, P Emery, D McGonagle*
- 196** Role of vascular channels as a novel mechanism for subchondral bone damage at cruciate ligament entheses in osteoarthritis and inflammatory arthritis  
*D A Binks, E M Gravallese, D Bergin, R J Hodgson, A L Tan, M M Matzelle, D McGonagle, A Radjenovic*
- 204** Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease  
*H Varsani, S C Charman, C K Li, S K N Marie, A A Amato, B Banwell, K E Bove, A M Corse, A M Emslie-Smith, T S Jacques, I E Lundberg, C Minetti, I Nennesmo, E J Rushing, A M E Sallum, C Sewry, C A Pilkington, J L Holton, L R Wedderburn, the UK Juvenile Dermatomyositis Research Group*
- 211** Absence of Fms-like tyrosine kinase 3 ligand (Flt3L) signalling protects against collagen-induced arthritis  
*M I P Ramos, O N Karpus, P Broekstra, S Aarass, S E Jacobsen, P P Tak, M C Lebré*
- 220** Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice  
*E Coste, I R Greig, P Mollat, L Rose, M Gray, S H Ralston, R J van 't Hof*
- 227** Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells  
*S Blüml, M Friedrich, T Lohmeyer, E Sahin, V Saferding, J Brunner, A Puchner, P Mandl, B Niederreiter, J S Smolen, G Schabbauer, K Redlich*
- 234** Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis  
*Y Rombouts, E Ewing, L A van de Stadt, M H J Selman, L A Trouw, A M Deelder, T W J Huizinga, M Wührer, D van Schaardenburg, R E M Toes, H U Scherer*
- 242** AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis  
*C S Bonnet, A S Williams, S J Gilbert, A K Harvey, B A Evans, D J Mason*
- 252** Increased function of pronociceptive TRPV1 at the level of the joint in a rat model of osteoarthritis pain  
*S Kelly, R J Chapman, S Woodhams, D R Sagar, J Turner, J J Burston, C Bullock, K Paton, J Huang, A Wong, D F McWilliams, B N Okine, D A Barrett, G J Hathway, D A Walsh, V Chapman*
- 260** FGF2 induces RANKL gene expression as well as IL1 $\beta$  regulated MHC class II in human bone marrow-derived mesenchymal progenitor stromal cells  
*C Bocelli-Tyndall, E Trela, A Frachet, P Zajac, D Pfaff, J Geurts, S Heiler, A Barbero, M Mumme, T J Resink, S Schaeren, G C Spagnoli, A Tyndall*
- 267** Inhibition of Notch signalling ameliorates experimental inflammatory arthritis  
*J-S Park, S-H Kim, K Kim, C-H Jin, K Y Choi, J Jang, Y Choi, A-R Gwon, S-H Baik, U J Yun, S Y Chae, S Lee, Y M Kang, K C Lee, T V Arumugam, M P Mattsson, J H Park, D-G Jo*
- 275** Articular chondrocyte network mediated by gap junctions: role in metabolic cartilage homeostasis  
*M D Mayan, R Gago-Fuentes, P Carpintero-Fernandez, P Fernandez-Puente, P Filgueira-Fernandez, N Goyanes, V Valiunas, P R Brink, G S Goldberg, F J Blanco*

## Basic and translational research

- 190** Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations  
*Z S Wallace, H Mattoo, M Carruthers, V S Mahajan, E D Torre, H Lee, M Kulikova, V Deshpande, S Pillai, J H Stone*

- 285** Inhibition of Rac1 activity by controlled release of NSC23766 from chitosan microspheres effectively ameliorates osteoarthritis development in vivo  
 *S Zhu, P Lu, H Liu, P Chen, Y Wu, Y Wang, H Sun, X Zhang, Q Xia, B C Heng, Y Zhou, H W Ouyang*


- 294** B cell resistance to Fas-mediated apoptosis contributes to their ineffective control by regulatory T cells in rheumatoid arthritis  
*L Rapetti, K-M Chavele, C M Evans, M R Ehrenstein*

- 303** Free fatty acids: potential proinflammatory mediators in rheumatic diseases  
*K W Frommer, A Schäffler, S Rehart, A Lehr, U Müller-Ladner, E Neumann*

- 311** The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region  
*K A van Schie, M H Hart, E R de Groot, S Kruithof, L A Aarden, G J Wolbink, T Rispens*

## Letters

- 315** Autologous stem cell transplantation leads to a change in proinflammatory plasma cytokine profile of patients with juvenile dermatomyositis correlating with disease activity  
*F B Enders, E M Delemarre, J Kuemmerle-Deschner, P van der Torre, N M Wulffraat, B P Prakken, A van Royen-Kerkhof, F van Wijk*

- 317** Antibodies to domain I of  $\beta$ -2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospholipid syndrome  
 *L Cousins, C Pericleous, M Khamashta, M L Bertolaccini, Y Ioannou, I Giles, A Rahman*

## Corrections

- 319** Corrections

## Electronic pages

- e1** Cadmium the missing link between smoking and increased rheumatoid disease activity?  
*M Cates, D Hutchinson*

- e2** Response to: 'Cadmium the missing link between smoking and increased rheumatoid disease activity?' by Cates and Hutchinson  
*C Ospelt, S Gay*

- e3** The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis  
*H W van Steenberghe, S Ajeganova, K Forslind, B Svensson, A H M van der Helm-van Mil*

- e4** The impact of rheumatoid factor and ACPA on bone erosion in rheumatoid arthritis  
*C Hecht, G Schett, S Finzel*

- e5** Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry  
*E G Favalli, A Becciolini, M Biggoggero, A Marchesoni, P L Meroni*

- e6** Response to: 'Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry' by Favalli *et al*  
*R Fleischmann, E Bananis*

- e7** PPAD remains a credible candidate for inducing autoimmunity in rheumatoid arthritis: comment on the article by König *et al*  
*A-M Quirke, K Lundberg, J Potempa, T R Mikuls, P J Venables*

- e8** PPAD is not targeted as a citrullinated protein in rheumatoid arthritis, but remains a candidate for inducing autoimmunity  
*M F König, C O Bingham III, F Andrade*

- e9** Risk of vascular disease with gout: overadjustment of the statistical analyses?  
*C M van Durme, B Spaetgens, A Boonen, F de Vries*

- e10** Response to: 'Risk of vascular disease with gout: overadjustment of the statistical analyses?' by van Durme *et al*  
*L Clarson, S L Hider, J Belcher, C Heneghan, E Roddy, C D Mallen*